Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.
Identifieur interne : 001482 ( Main/Exploration ); précédent : 001481; suivant : 001483Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.
Auteurs : RBID : pubmed:21476058English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Octreotide.
- chemical , analogs & derivatives : Octreotide.
- pathology : Neuroendocrine Tumors.
- radiotherapy : Neuroendocrine Tumors.
- chemical , therapeutic use : Octreotide.
- Adult, Aged, Female, Humans, Male, Middle Aged, Radiation Dosage, Radiotherapy Dosage, Retrospective Studies, Treatment Outcome.
Abstract
This study aimed to assess the outcome of high-dose In-111 octreotide treatment and efficacy of long-acting Sandostatin LAR in patients with disseminated neuroendocrine tumors.
DOI: 10.1007/s12149-011-0482-2
PubMed: 21476058
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.</title><author><name sortKey="Ozkan, Elgin" uniqKey="Ozkan E">Elgin Ozkan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, Ankara University Faculty of Medicine, Ankara, Turkey. ozkanelgin@yahoo.com</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Nuclear Medicine, Ankara University Faculty of Medicine, Ankara</wicri:regionArea></affiliation></author><author><name sortKey="Tokmak, Emel" uniqKey="Tokmak E">Emel Tokmak</name></author><author><name sortKey="Kucuk, N Ozlem" uniqKey="Kucuk N">N Ozlem Kucuk</name></author></titleStmt><publicationStmt><date when="2011">2011</date><idno type="doi">10.1007/s12149-011-0482-2</idno><idno type="RBID">pubmed:21476058</idno><idno type="pmid">21476058</idno><idno type="wicri:Area/Main/Corpus">001442</idno><idno type="wicri:Area/Main/Curation">001442</idno><idno type="wicri:Area/Main/Exploration">001482</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuroendocrine Tumors (pathology)</term><term>Neuroendocrine Tumors (radiotherapy)</term><term>Octreotide (adverse effects)</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (therapeutic use)</term><term>Radiation Dosage</term><term>Radiotherapy Dosage</term><term>Retrospective Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Radiation Dosage</term><term>Radiotherapy Dosage</term><term>Retrospective Studies</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study aimed to assess the outcome of high-dose In-111 octreotide treatment and efficacy of long-acting Sandostatin LAR in patients with disseminated neuroendocrine tumors.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21476058</PMID><DateCreated><Year>2011</Year><Month>07</Month><Day>11</Day></DateCreated><DateCompleted><Year>2011</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1864-6433</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of nuclear medicine</Title><ISOAbbreviation>Ann Nucl Med</ISOAbbreviation></Journal><ArticleTitle>Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.</ArticleTitle><Pagination><MedlinePgn>425-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12149-011-0482-2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aimed to assess the outcome of high-dose In-111 octreotide treatment and efficacy of long-acting Sandostatin LAR in patients with disseminated neuroendocrine tumors.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A total of 14 patients (mean age 51.8 ± 13.2 years; 10 female, 4 male) receiving high-dose In-111 octreotide in our centre for the treatment of neuroendocrine tumors were included in the study. Monthly treatment with long-acting somatostatin analogue [Sandostatin long-acting release (Novartis Pharmaceuticals)] was continued in nine cases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During a 3-year period, a total of 45 courses of high-dose In-111 octreotide treatment were delivered to 14 patients. In seven patients receiving an average of four treatment courses (6 carcinoid tumors, 1 thymoma, patients: 2, 4, 5, 11-14) stable disease was achieved (50%). In two patients with carcinoid tumors (patients 1 and 3) who received four treatment courses, partial response was observed (14%). Five patients (36%; 4 NET, 1 gastrinoma; patients 6-10) died due to progressive disease following on average two treatment courses. On average, deaths occurred 2 months after the last treatment dose. No complete responses were seen. Partial response was achieved in two of the nine patients receiving Sandostatin LAR, while four had stable disease. Both treatments were associated with acceptable tolerability.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High-dose In-111 octreotide can be safely administered in conjunction with somatostatin analogue in patients with disseminated NET and this treatment may help to stabilize the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ozkan</LastName><ForeName>Elgin</ForeName><Initials>E</Initials><Affiliation>Department of Nuclear Medicine, Ankara University Faculty of Medicine, Ankara, Turkey. ozkanelgin@yahoo.com</Affiliation></Author><Author ValidYN="Y"><LastName>Tokmak</LastName><ForeName>Emel</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kucuk</LastName><ForeName>N Ozlem</ForeName><Initials>NO</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Ann Nucl Med</MedlineTA><NlmUniqueID>8913398</NlmUniqueID><ISSNLinking>0914-7187</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium-111-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName><QualifierName MajorTopicYN="Y">pathology</QualifierName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="N">adverse effects</QualifierName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Radiation Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiotherapy Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1007/s12149-011-0482-2</ArticleId><ArticleId IdType="pubmed">21476058</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001482 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001482 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21476058
|texte= Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21476058" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |